Appetite loss and malnutrition are among the most serious yet underrecognized health concerns affecting older adults worldwide. Malnutrition — meaning the body is not getting enough essential nutrients — affects an estimated 22% to 23% of community-dwelling older adults globally, with rates climbing sharply in hospital and care home settings. These conditions contribute to muscle wasting, weakened immunity, slower recovery from illness, and reduced quality of life.
Tetrahydrocannabinol, commonly known as THC, the primary psychoactive compound in cannabis, has recently attracted attention as a potential tool to stimulate appetite in elderly patients. This article aims to evaluate the current scientific evidence both supporting and questioning THC’s role as a therapeutic option in geriatric care. Given that older adults are more vulnerable to medication side effects, any emerging treatment must be assessed with caution, precision, and a strong foundation in evidence-based medicine.
The Scope of Appetite Loss and Malnutrition in Older Adults
Malnutrition among older adults is a serious and widespread public health concern. According to the World Health Organization and multiple large-scale studies, an estimated 15–30% of community-dwelling older adults and up to 60% of hospitalized elderly patients show signs of malnutrition or significant nutritional risk. These numbers vary by region, income level, and care setting, but the problem is consistently documented across both high-income and low-income countries.
The following table illustrates the variation in malnutrition prevalence across different regions and care settings.
| Region | Community Setting | Hospital Setting | Long-Term Care |
|---|---|---|---|
| North America | 5–10% | 40–55% | 25–60% |
| Europe | 10–20% | 35–50% | 30–55% |
| Asia-Pacific | 15–30% | 45–60% | 40–65% |
| Sub-Saharan Africa | 20–35% | 50–65% | Limited data |
| Latin America | 10–25% | 40–58% | 30–50% |
Clinicians distinguish between primary malnutrition — caused directly by insufficient food intake — and secondary malnutrition, which results from underlying diseases that interfere with how the body absorbs or uses nutrients.
Key Risk Factors
Several key risk factors drive appetite loss in aging:
- Physiological changes: Reduced senses of taste and smell, poor dental health, and hormonal shifts that suppress hunger signals all contribute meaningfully.
- Social and psychological factors: Loneliness, depression, and grief following bereavement frequently reduce motivation to eat.
- Polypharmacy: Many older adults take multiple medications simultaneously, and common drug side effects include nausea, dry mouth, and appetite suppression.
- Chronic illness and hospitalization: Conditions such as cancer, heart failure, and dementia directly interfere with appetite and nutrient absorption.
The consequences of untreated malnutrition are severe. They include increased mortality risk, accelerated physical frailty, cognitive decline, weakened immune function, and significantly longer hospital stays.
Why Appetite Regulation Becomes Compromised in Aging
Appetite is not simply a matter of willpower or habit — it is tightly controlled by biological systems that change significantly as people age. One well-recognized condition is anorexia of aging, a clinically documented reduction in appetite and food intake unrelated to depression or illness alone. Its biological roots include hormonal shifts, slowed digestion, and nervous system changes.
Two key hormones illustrate this imbalance. Ghrelin — the body’s primary hunger signal — loses effectiveness with age, meaning the brain receives weaker “time to eat” messages. Meanwhile, leptin, a hormone that signals fullness, remains elevated longer than it should, creating a prolonged sense of satiety even after minimal food intake. Add to this slowed gut motility — the digestive tract moves food more sluggishly — and older adults feel full faster and longer.
Neurological conditions like dementia and Parkinson’s disease further disrupt appetite by impairing the brain circuits that recognize hunger and coordinate eating behavior.
The endocannabinoid system (ECS) — a network of receptors and natural chemical messengers throughout the body — plays a central role in appetite regulation. ECS activity at CB1 receptors in the hypothalamus (the brain’s hunger control center) stimulates hunger and enhances the pleasure of eating. However, aging progressively reduces ECS sensitivity, meaning these hunger-promoting signals weaken over time. This natural decline in ECS function provides a logical biological rationale for exploring cannabinoid-based interventions to restore appetite in elderly individuals.
What Is THC and How Does It Affect Appetite?
Tetrahydrocannabinol (THC) is the primary psychoactive compound found in the cannabis plant. Pharmacologically, it is classified as a partial agonist of the endocannabinoid system — meaning it activates specific receptors in the body that regulate mood, pain, memory, and appetite.
THC primarily binds to two receptor types: CB1 receptors, concentrated in the brain and central nervous system, and CB2 receptors, found mainly in immune tissues. When THC activates CB1 receptors in the hypothalamus — the brain region controlling hunger — it triggers appetite signals, essentially telling the body it is time to eat.
Beyond the brain, THC enhances sensitivity to smell and taste, making food more appealing. It also increases ghrelin, a hormone that signals hunger, while simultaneously reducing nausea, which further improves willingness to eat.
Unlike THC, cannabidiol (CBD) does not strongly stimulate appetite and lacks significant psychoactive effects.
FDA/EMA-Approved or Regulated THC-Based Pharmaceuticals
The following table summarizes the key pharmaceutical THC-based medications that have received regulatory approval or recognition.
| Medication | Active Compound | Indication | Dosage Form | Regulatory Status |
|---|---|---|---|---|
| Dronabinol (Marinol) | Synthetic THC | Appetite loss in AIDS; chemotherapy nausea | Oral capsule | FDA-approved |
| Nabilone (Cesamet) | Synthetic THC analog | Chemotherapy-induced nausea | Oral capsule | FDA/Health Canada approved |
| Nabiximols (Sativex) | THC + CBD | Spasticity in multiple sclerosis | Oromucosal spray | EMA-approved (select countries) |
These approved formulations represent the current landscape of regulated THC-based medicines available for clinical use.
Review of Current Clinical Evidence: THC in Elderly Patients
The body of research examining THC as an appetite stimulant in older adults remains relatively limited but is steadily growing. Most available evidence comes from studies on dronabinol — a synthetic, pharmaceutical-grade form of THC approved by the FDA — rather than whole-plant cannabis. These studies have been conducted primarily in populations with cancer cachexia (severe weight loss linked to cancer), HIV/AIDS-related wasting, and dementia, particularly Alzheimer’s disease.
Key Studies and Their Findings
Randomized Controlled Trials (RCTs)
Early RCTs on dronabinol in cancer cachexia showed modest improvements in appetite but limited gains in body weight. A notable trial by Jatoi et al. (2002) compared dronabinol to megestrol acetate (a standard appetite stimulant) in cancer patients and found megestrol significantly more effective for weight gain. However, dronabinol was better tolerated by some participants.
In dementia-specific populations, a small Dutch study by Volicer et al. demonstrated that low-dose dronabinol improved food intake and reduced agitation in Alzheimer’s patients — a particularly meaningful finding given how behavioral symptoms worsen nutritional decline.
Observational Studies
Observational data from geriatric medical cannabis programs, particularly in Israel and parts of the United States, suggest broader benefits. Patients reported improvements in appetite, sleep quality, and overall mood, supporting a better quality of life. However, these studies lack the controlled conditions needed to confirm direct causation.
Summary of Key Clinical Studies
The following table provides an overview of the most relevant clinical studies examining THC’s effects on appetite and related outcomes in elderly and seriously ill populations.
| Study | Type | Population | THC Form/Dose | Outcome Measures | Results | Limitations |
|---|---|---|---|---|---|---|
| Jatoi et al. (2002) | RCT | Cancer cachexia | Dronabinol 2.5mg twice daily | Weight, appetite, quality of life | Less effective than megestrol for weight gain | Short duration; mostly younger adults |
| Volicer et al. (1997) | RCT | Alzheimer’s disease | Dronabinol 2.5mg daily | Food intake, body weight, agitation | Improved intake; reduced agitation | Very small sample (n=15) |
| Brisbois et al. (2011) | RCT | Advanced cancer | Dronabinol vs. placebo | Caloric intake, taste perception | Increased caloric intake; improved taste | Short duration (18 days) |
| Minerbi et al. (2019) | Observational | Geriatric patients (>65) | Whole cannabis (varied) | Appetite, pain, sleep, quality of life | Significant improvement in appetite and wellbeing | No control group; self-reported data |
| Shelef et al. (2016) | Observational | Dementia patients | Medical cannabis oil | Weight, behavioral symptoms | Weight stabilization; behavioral improvement | Small sample; no placebo group |
Across studies, THC produced modest but measurable improvements in appetite and caloric intake. Outcomes varied by condition. Patients with HIV/AIDS-related wasting showed more consistent weight responses than those with cancer cachexia, where the disease process itself strongly resists nutritional intervention. In dementia populations, the appetite benefit appeared closely linked to reduced agitation and improved behavioral symptoms, suggesting THC’s effect may be partly indirect.
Limitations of Current Research
The existing evidence carries significant weaknesses that prevent definitive conclusions:
- Small sample sizes — most trials enrolled fewer than 50 participants
- Short durations — many studies lasted under 6 weeks
- No large-scale geriatric-specific RCTs — older adults are frequently underrepresented
- Heterogeneity in formulations and dosing — making cross-study comparisons difficult
These limitations collectively highlight the urgent need for more rigorous, geriatric-focused research before definitive clinical recommendations can be made.
THC vs. Conventional Appetite Stimulants
The following table compares THC (dronabinol) with other commonly used appetite stimulants across several clinically relevant dimensions.
| Feature | THC (Dronabinol) | Megestrol Acetate | Mirtazapine | Corticosteroids |
|---|---|---|---|---|
| Efficacy for appetite | Modest | High (short-term) | Moderate | Moderate (short-term) |
| Weight gain evidence | Limited | Strongest available | Moderate | Limited |
| Side effects in elderly | Dizziness, confusion, sedation | Thrombosis, adrenal suppression | Sedation, falls risk | Hyperglycemia, bone loss, immune suppression |
| Cost | Moderate–High | Moderate | Low | Low |
| Ease of use | Oral capsule or oil | Oral liquid/tablet | Oral tablet | Oral or injectable |
| Suitability for elderly | Caution required | Caution required | Generally suitable | Short-term use only |
Compared to megestrol acetate, THC carries a lower risk of dangerous blood clots, making it potentially safer for older adults with cardiovascular concerns. However, its psychoactive side effects require careful monitoring. Current evidence suggests THC may serve best as a secondary option when standard treatments are poorly tolerated or ineffective.
Safety Profile of THC in the Elderly: Key Considerations
Older adults do not process THC the same way younger people do. With age, the body’s metabolism slows down, meaning THC stays in the system longer and produces stronger or more prolonged effects. Additionally, older adults tend to have higher body fat percentages, and since THC is fat-soluble, it can accumulate in tissues and release gradually, extending its impact unpredictably.
Aging also increases sensitivity to THC’s psychoactive effects, meaning smaller doses can cause significant reactions. Combined with the reality that many older adults take multiple medications — a situation called polypharmacy — the risk of harmful drug interactions becomes a serious clinical concern.
Documented Adverse Effects in Elderly Users
THC use in older adults is associated with several well-documented risks:
- Psychomotor impairment and fall risk: THC affects coordination and balance, significantly increasing fall risk — a leading cause of injury-related death in elderly populations.
- Cognitive effects: Confusion, memory disruption, and delirium (sudden severe mental confusion) have been reported, particularly in those with existing cognitive vulnerability.
- Cardiovascular effects: THC can cause tachycardia (rapid heartbeat) and orthostatic hypotension (a sudden blood pressure drop when standing), both dangerous for older hearts.
- Psychiatric symptoms: Anxiety, paranoia, and worsening of mood disorders can occur, especially at higher doses.
- Dependency risk: While lower in older adults compared to younger users, psychological dependence remains a possibility with regular use.
These adverse effects underscore the importance of careful patient selection and ongoing clinical monitoring when considering THC in elderly populations.
High-Risk Drug Interactions Between THC and Common Geriatric Medications
The following table outlines the most clinically significant drug interactions between THC and medications commonly prescribed to older adults.
| Medication Class | Potential Interaction |
|---|---|
| Anticoagulants (e.g., warfarin) | Increased bleeding risk |
| Sedatives/benzodiazepines | Enhanced sedation, respiratory depression |
| Antihypertensives | Compounded blood pressure lowering |
| Antidepressants (e.g., SSRIs) | Altered mood regulation, serotonin disruption |
| Antiepileptics | Changed seizure threshold |
THC is contraindicated — meaning it should not be used — in individuals with dementia involving psychotic features, severe cardiovascular disease, or a history of psychosis. The guiding principle for geriatric use is “start low, go slow,” beginning with the lowest effective dose and increasing gradually under medical supervision. Regular monitoring by a healthcare provider remains essential to managing risks responsibly.
Legal, Ethical, and Access Considerations
The legal standing of medical cannabis and THC varies enormously across the world, directly shaping whether elderly patients can realistically access these treatments. Some countries permit THC-based medicines under strict medical supervision, while others classify cannabis as a controlled substance with no recognized therapeutic use.
The following table provides a comparative overview of the regulatory status of medical THC and cannabis across key countries and regions.
| Country/Region | Status | Notes |
|---|---|---|
| United States | Varies by state | Federally restricted; 38+ states allow medical use |
| Canada | Legal/Regulated | Nationally legal for medical and recreational use |
| Germany | Regulated | Prescription-based medical cannabis permitted |
| Netherlands | Regulated | Pharmacy-dispensed medical cannabis available |
| Australia | Regulated | Accessible via authorized prescribers |
| United Kingdom | Restricted | Limited specialist prescriptions only |
| Brazil | Restricted | Approved for specific conditions |
| Japan | Illegal | Strictly prohibited |
| Russia | Illegal | No medical exceptions recognized |
| South Africa | Restricted | Personal use decriminalized; medical access limited |
Ethical concerns are equally significant. Patients with dementia or cognitive decline may lack full capacity to provide informed consent — meaning they cannot completely understand and agree to treatment independently. This creates tension between respecting patient autonomy and the protective role of caregivers and physicians. Additionally, older generations frequently carry deep stigma toward cannabis, associating it with recreational drug use rather than medicine.
Access barriers further complicate matters. THC-based treatments often carry high out-of-pocket costs, and insurance coverage remains inconsistent globally. Many geriatric specialists lack adequate training in cannabis therapeutics, limiting confident prescribing. Regulatory differences between pharmaceutical-grade THC products and non-pharmaceutical cannabis preparations create additional confusion for both clinicians and patients.
Practical Clinical Guidance: When and How to Consider THC
THC is not a first-choice treatment for appetite loss in older adults. Clinicians should consider it only after standard approaches have failed. Suitable candidates typically include older patients with refractory appetite loss — meaning their reduced appetite has not responded to dietary counseling, nutritional supplements, or appetite-stimulating medications like megestrol acetate. Patients experiencing overlapping symptoms such as chronic pain, nausea, or sleep disturbance may benefit more, since THC can address several of these issues simultaneously. Conversely, patients with a history of psychosis, severe dementia, unstable heart conditions, or high fall risk are generally not appropriate candidates due to significant safety concerns.
For elderly patients, pharmaceutical-grade oral formulations such as dronabinol capsules are strongly preferred over smoked or vaped cannabis. Oral forms allow precise, consistent dosing and easier titration — gradually increasing the dose from the lowest effective amount to minimize side effects.
Clinicians should track nutritional intake, body weight, cognitive function, physical stability, and any adverse events on a scheduled basis throughout treatment.
Effective management requires collaboration among a geriatrician, registered dietitian, pharmacist, and mental health professional to ensure coordinated, safe care.
First-Line Non-Pharmacological Interventions for Appetite Loss in the Elderly
These strategies should always be attempted before considering THC:
| Intervention | Description |
|---|---|
| Dietary modifications | Offer small, frequent, nutrient-dense meals |
| Meal timing | Align meals with peak appetite periods, often morning |
| Social eating | Encourage shared mealtimes to improve motivation |
| Oral health care | Address dental pain, dry mouth, or ill-fitting dentures |
| Food preference accommodation | Serve culturally familiar, personally preferred foods |
| Texture modification | Adjust food texture for chewing or swallowing difficulties |
| Appetite stimulating beverages | Use fortified smoothies or oral nutritional supplements |
| Physical activity | Light exercise before meals can naturally stimulate hunger |
Implementing these non-pharmacological strategies as a first step ensures that the least invasive and safest approaches are prioritized before pharmacological options such as THC are considered.
Future Directions in Research and Clinical Practice
Despite growing interest in THC for appetite loss in older adults, significant knowledge gaps remain. Large-scale, geriatric-specific randomized controlled trials (RCTs) — studies where participants are randomly assigned to treatment or placebo groups — are urgently needed. Current evidence relies heavily on small samples or younger populations. Long-term safety data in older adults, particularly regarding cognitive and cardiovascular effects, remain insufficient. Optimal dosing and formulation studies are also lacking.
Emerging research is exploring synthetic cannabinoids and selective CB1 agonists — compounds that target specific receptors with fewer psychoactive side effects. Combination THC-CBD therapies may offer appetite benefits while reducing unwanted mental effects. Personalized medicine approaches, using an individual’s endocannabinoid system (ECS) genetics to guide treatment, represent a promising frontier.
Policy bodies should consider updating geriatric prescribing guidelines to include structured frameworks for cannabis-based medicines, ensuring clinicians have clear, evidence-based guidance when treating older patients.
Conclusion
Appetite loss and malnutrition represent serious, often underrecognized burdens in older adults, contributing to muscle wasting, weakened immunity, and declining quality of life. THC, the psychoactive compound in cannabis, interacts with the body’s endocannabinoid system in ways that may stimulate hunger and improve caloric intake, offering a biologically plausible rationale for its use. However, existing clinical evidence remains modest, inconsistent, and largely drawn from studies not specifically designed for frail older populations. Meanwhile, safety concerns — including cognitive impairment, fall risk, and drug interactions — are particularly significant in this age group. THC should therefore be considered a last-resort adjunct only after conventional nutritional interventions have been exhausted. Rigorous, geriatric-focused clinical trials are urgently needed to establish clear, evidence-based guidelines. Above all, any decision to use THC must be individualized, carefully supervised, and grounded in honest, ethically responsible clinical judgment.